SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
What is the impact of intellectual property rules on access to medicines? A systematic review
16 references·0 citing·47 second hop
What is the impact of intellectual property rules on access to medicines? A systematic review (2022)What is the impact of intellectual proper…May your drug price be evergreen (2018)May your drug price be evergr…The health impact of trade and investment agreements: a quantitative systematic review and network co-citation analysis (2017)The health impact of trade an…Policy objective of generic medicines from the investment perspective: The case of clopidogrel (2017)Policy objective of generic m…Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry (2016)Regulation and welfare: evide…The Market Impacts of Pharmaceutical Product Patents in Developing Countries: Evidence from India (2015)The Market Impacts of Pharmac…Patents and the Global Diffusion of New Drugs (2015)Patents and the Global Diffus…Trends in Compulsory Licensing of Pharmaceuticals Since the Doha Declaration: A Database Analysis (2012)Trends in Compulsory Licensin…Polymorphs and Prodrugs and Salts (Oh My!): An Empirical Analysis of “Secondary” Pharmaceutical Patents (2012)Polymorphs and Prodrugs and S…Evergreening, patent challenges, and effective market life in pharmaceuticals (2012)Evergreening, patent challeng…A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries (2010)A lifeline to treatment: the …The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration (2009)The PRISMA statement for repo…TRIPS-Plus Free Trade Agreements and Access to Medicines (2007)TRIPS-Plus Free Trade Agreeme…Estimating the Effects of Global Patent Protection in Pharmaceuticals: A Case Study of Quinolones in India (2006)Estimating the Effects of Glo…Appraising the Evidence: Reviewing Disparate Data Systematically (2002)Appraising the Evidence: Revi…Access to Essential Drugs in Poor Countries (1999)Access to Essential Drugs in …Generic Entry and the Pricing of Pharmaceuticals (1997)Generic Entry and the Pricing…Economic Welfare and the Allocation of Resources for Invention (1962)Markov-Perfect Industry Dynamics: A Framework for Empirical Work (1995)Do free trade agreements actually increase members' international trade? (2006)A double-edged sword? The antipodal effects of institutional distance on partner selection in cross-border alliances (2018)Pooled procurement of drugs in low and middle income countries (2021)Limit Pricing and Entry under Incomplete Information: An Equilibrium Analysis (1982)Optimal Patent Length and Breadth (1990)Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry (2004)Automatic Reaction - What Happens to Workers at Firms that Automate? (2019)For whom the bell tolls: The firm-level effects of automation on wage and gender inequality (2022)What Happens to Workers at Firms that Automate? (2023)Patents and Innovation: An Empirical Study (1986)Appropriating the Returns from Industrial Research and Development (1987)The productivity crisis in pharmaceutical R&D (2011)Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules (2015)Secondary Pharmaceutical Patenting: A Global Perspective (2017)Mapping Markush (2022)Systematic Reviews: Rationale for systematic reviews (1994)Defining and Designing Mixed Research Synthesis Studies. (2006)Using qualitative metasummary to synthesize qualitative and quantitative descriptive findings (2007)Searching for qualitative research for inclusion in systematic reviews: a structured methodological review (2016)How Do Patents And Economic Policies Affect Access To Essential Medicines In Developing Countries? (2004)Trade, TRIPS, and pharmaceuticals (2009)WHO Model Lists of Essential Medicines (2016)ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe (2017)Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001–2016 (2018)Access to medicines after TRIPS: Is compulsory licensing an effective mechanism to lower drug prices? A review of the existing evidence (2020)Measuring inconsistency in meta-analyses (2003)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (2009)Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement (2009)The PRISMA 2020 statement: an updated guideline for reporting systematic reviews (2021)The PRISMA 2020 statement: an updated guideline for reporting systematic reviews (2021)The PRISMA 2020 statement: An updated guideline for reporting systematic reviews (2021)An Almost Ideal Demand System (1980)Economics and Consumer Behavior (1980)Automobile Prices in Market Equilibrium (1995)Investments in Pharmaceuticals Before and After TRIPS (2011)Econometric Analysis of Cross Section and Panel Data (2001)Innovation and Its Discontents: How Our Broken Patent System Is Endangering Innovation and Progress, and What to Do About It (2005)Innovation and Its Discontents (2011)Secondary Patenting Of Branded Pharmaceuticals: A Case Study Of How Patents On Two HIV Drugs Could Be Extended For Decades (2012)Pharmaceuticals and the Developing World (2002)Access to medicines from a health system perspective (2012)The drug and vaccine landscape for neglected diseases (2000–11): a systematic assessment (2013)Review of the literature on reference pricing (2000)Parallel imports and the pricing of pharmaceutical products: evidence from the European Union (2004)Consumer learning and heterogeneity: Dynamics of demand for prescription drugs after patent expiration (2010)
this work references cited by second hop

References

  • 2009The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration10,571 cited
  • 2002Appraising the Evidence: Reviewing Disparate Data Systematically1,216 cited
  • 1999Access to Essential Drugs in Poor Countries396 cited
  • 2006Estimating the Effects of Global Patent Protection in Pharmaceuticals: A Case Study of Quinolones in India288 cited
  • 2012Evergreening, patent challenges, and effective market life in pharmaceuticals262 cited
  • 1997Generic Entry and the Pricing of Pharmaceuticals260 cited
  • 2015Patents and the Global Diffusion of New Drugs185 cited
  • 2015The Market Impacts of Pharmaceutical Product Patents in Developing Countries: Evidence from India184 cited
  • 2012Polymorphs and Prodrugs and Salts (Oh My!): An Empirical Analysis of “Secondary” Pharmaceutical Patents170 cited
  • 2012Trends in Compulsory Licensing of Pharmaceuticals Since the Doha Declaration: A Database Analysis166 cited
  • 2010A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries154 cited
  • 2017The health impact of trade and investment agreements: a quantitative systematic review and network co-citation analysis140 cited
  • 2017Policy objective of generic medicines from the investment perspective: The case of clopidogrel136 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

2016
Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry
124 cited
  • 2018May your drug price be evergreen109 cited
  • 2007TRIPS-Plus Free Trade Agreements and Access to Medicines104 cited
  • Cited by

    No citing works inside the corpus for this window.